- RAPID SCREENING FOR SARS-CoV-2 VARIANTS OF CONCERN IN CLINICAL AND
- 2 ENVIRONMENTAL SAMPLES USING NESTED RT-PCR ASSAYS TARGETING KEY
- 3 MUTATIONS OF THE SPIKE PROTEIN

- 7 La Rosa G. 1\*, Mancini P. 1, Bonanno Ferraro G. 1, Veneri C. 1, Iaconelli M. 1, Lucentini L. 1, Bonadonna
- 8 L.<sup>1</sup>, Brusaferro S.<sup>2</sup>, Brandtner D.<sup>3</sup>, Fasanella A.<sup>4</sup>, Pace L.<sup>4</sup>, Parisi A.<sup>4</sup>, Galante D.<sup>4</sup>, Suffredini E.<sup>5</sup>
- 10 Department of Environment and Health, Italian National Institute of Health, Rome, Italy.
- 11 <sup>2</sup> Office of the President, Istituto Superiore di Sanità, Rome, Italy
- 12 <sup>3</sup> Independent Researcher, Rome, Italy.
- <sup>4</sup> Experimental Zooprophylactic Institute of the Apulia and Basilicata Regions, Foggia, Italy.
- <sup>5</sup> Department of Food Safety, Nutrition and Veterinary Public Health, Italian National Institute of
- 15 Health, Rome, Italy.

5

6

9

16

17

# \*Corresponding author:

Giuseppina La Rosa

Department of Environment and Health

Italian National Institute of Health, Rome, Italy

Phone: +390649902718

Email: giuseppina.larosa@iss.it

### **SUMMARY**

18

19

24

27

34

35

36

37

41

20 New SARS-CoV-2 mutations are constantly emerging, raising concerns of increased 21 transmissibility, virulence or escape from host immune response. 22 We describe a nested RT-PCR assay (~1500 bps) to detect multiple key spike protein mutations 23 distinctive of the major known circulating SARS-CoV-2 variants, including the three Variants of Concern (VOCs) 20I/501Y.V1 (United Kingdom), 20H/501Y.V2 (South Africa), and 20J/501Y.V3 (Brazil), as well as the 20E.EU1 variant (Spain), the CAL.20C recently identified in California, and 25 the mink-associated variant (GR, lineage B.1.1.298). Prior to application to field samples, the 26 discriminatory potential of this PCR assay was explored using GISAID and Nextclade. To extend variant detection to challenging matrices such as sewage, where the amplification of long fragments 28 29 is problematic, two short nested RT-PCR assays (~300 bps) were also designed, targeting portions of the region spanned by the long nested assay. 30 The three newly-designed assays were then tested on field samples, including 7 fully-sequenced 31 32 viral isolates from swab samples and 34 urban wastewater samples, some of which collected in 33 areas where circulation of VOCs had been reported. The long assay successfully amplified all the previously characterized viral isolates, allowing the correct identification of variants 20I/501Y.V1 and 20E.EU1 present in the panel. The sequences obtained using the short assays were consistent with those obtained with the long assay. Mutations characteristic of VOCs (UK and Brazilian variant) and of other variant (Spanish) were detected in sewage samples. To our knowledge, this is the first evidence of the presence of sequences harboring 38 key mutations of 20I/501Y.V1 and 20J/501Y.V3 in urban wastewaters, highlighting the potential 39 40 contribution of wastewater surveillance to explore SARS-CoV-2 diversity. The developed nested RT-PCR assays can be used as an initial rapid screening test to select clinical 42 samples containing mutations of interest. This can speed up diagnosis and optimize resources since 43 it allows full genome sequencing to be done only on clinically relevant specimens. The assays can

be also employed for a rapid and cost-effective detection of VOCs or other variants in sewage for

the purposes of wastewater-based epidemiology. The approach proposed here can be used to better

understand SARS-CoV-2 variant diversity, geographic distribution and impact worldwide.

**Keywords:** SARS-CoV-2, variant, mutation, VOC, PCR, sequencing

## INTRODUCTION

44

45

46

47

48

49

50

51

52

53

54

56

57

58

59

60

63

64

66

67

55 On 31 December 2019, the Wuhan Municipal Health and Health Commission reported a cluster of

pneumonia cases of unknown aetiology. Further investigations identified a novel coronavirus as the

causative agent of the disease (China CDC, 2020). On 11 March 2020, following the spread of the

outbreak to other parts of China and to a number of countries worldwide, the Director General of

the WHO declared the COVID-19 outbreak a pandemic (WHO, 2020a). As of 23 February 2021,

111 million cases have been documented in 192 countries, with 2.4 million confirmed deaths

61 (https://coronavirus.jhu.edu/map.html).

62 A growing number of SARS-CoV-2 variant sequences are being detected since the beginning of the

pandemic, some of which considered of global concern. All of these variants have characteristic

mutations, the most significant of which are located in the gene encoding the spike (S) protein,

65 potentially affecting viral infectivity and antigenicity (Li et al., 2020; Pillay et al., 2020).

One mutation in the spike protein (D614G), in particular, emerged early in the epidemic and spread

rapidly through Europe and North America (Korber et al., 2020; Volz et al., 2020).

In August/September 2020, a SARS-CoV-2 variant linked to infection among farmed minks, 68 subsequently transmitted to humans, was identified in Denmark (Hammer et al., 2020). In all, six 69 70 countries (Denmark, the Netherlands, Spain, Sweden, Italy and the United States) reported cases of farmed mink infected with SARS-CoV-2 to the World Organisation for Animal Health (OIE) 71 (WHO, 2020b). 72 An additional novel variant - clade GV, lineage B.1.177 (GISAID) or 20E.EU1 (Nexstrain) -73 emerged in early summer of 2020 in Spain, and subsequently spread to multiple locations in 74 Europe, possibly introduced into other countries by summer tourists (Hodcroft et al., 2020). The 75 introduction of the B.1.177 lineage into Ontario, Canada, by a traveller returning from Europe in 76 late September 2020 was also reported in a recent preprint (Guthrieet al., 2020). 77 On 14 December 2020, British authorities announced that a new SARS-CoV-2 variant had been 78 identified through viral genomic sequencing (WHO, 2020c). The variant was initially termed 79 SARS-CoV-2 VUI 202012/01 (Variant Under Investigation, year 2020, month 12, variant 01) and 80 then re-designated VOC (Variant Of Concern) 202012/01 on 18 December 2020 (Chand et al., 81 82 2021). The new variant belongs to clade GR, lineage B.1.1.7 (GISAID), or clade 20I/501Y.V1 83 (Nextstrain) and was discovered following an unforeseen rise in COVID-19 cases in South East 84 England, with a more than three-fold increase in the period from 5 October to 13 December 2020 85 (WHO, 2020d). As of 19 January 2021, 23 EU/EEA countries, including Italy, have reported the new COVID-19 variant 20I/501Y.V1. In the rest of the world, 37 additional countries reported it 86 (ECDC, 2021b). The emergence of the new SARS-CoV-2 variant, which could be 40-70% more 87 transmissible than previous strains circulating in the UK (WHO 2020b; ECDC, 2020), has 88 prompted some countries to close their borders with the UK. A review by the UK's New and 89 90 Emerging Respiratory Virus Threats Advisory Group (NERVTAG) advises that there is moderate confidence that 20I/501Y.V1 has a substantial increase in transmissibility compared to other 91 variants (NERVTAG, 2020; Mahase 2020). However, there is not enough information at present to 92

93 determine whether this variant is associated with any change in clinical disease severity or increased 94 mortality, though preliminary analyses in the United Kingdom, showed a risk ratio of death of 1.65 95 for B.1.1.7 cases compared to non-B.1.1.7 cases (PHE, 2021). As for antigenic response, to date, it 96 is considered unlikely that 20I/501Y.V1 may hinder vaccine-induced immunity (Conti et al., 2021). On 18 December 2020, national authorities in South Africa announced the detection of a new 97 98 variant of SARS-CoV-2, designated VOC-202012/02 (the second Variant Of Concern, December 2020). This variant, belonging to clade GH, lineage B.1.351 (GISAID) or 20H/501Y.V2 99 100 (Nextstrain), was reported to be largely replacing other coronavirus strains in South Africa since at 101 least November 2020. As of 19 January 2021, 10 EU/EEA countries (Germany, France, Ireland, 102 Austria, Belgium, Finland, the Netherlands, Norway and Sweden) and 13 countries/territories outside of the EU/EEA have documented the presence of this new SARS-CoV-2 variant (ECDC, 103 104 2021b). One case of the South African variant was detected in Italy, in a man who landed at Milan's of 105 Malpensa Airport from Africa at the end January (https://www.ansa.it/lombardia/notizie/2021/02/03/a-varese-primo-caso-variante-sudafricana-in-106 107 italia\_41b99448-367c-4000-ac88-9b3ae130d839.html). Preliminary results indicate that it may have 108 increased transmissibility. Here too, as with the VOC 202012/01 variant, there is no evidence that it 109 is associated with a higher severity of infection (ECDC, 2021b). In January, another variant, clade GR lineage P.1 (GISAID) or 20J/501Y.V3 (Nextrain) was 110 identified in Japan in four travellers who had arrived from Brazil (NIID, 2021; Galloway et al., 111 2021). Whole genome sequences for all four isolates were deposited in GISAID EpiCoV on 10 112 January 2021. On 13 January 2021, researchers from Fiocruz Amazônia announced the 113 114 identification of this variant in the capital of Amazonas, Manaus, where an upsurge in COVID-19 115 cases was registered in January of 2021 (Farias et al., 2021). To date, the P.1 variant has been 116 identified either in Brazil, or in travellers from Brazil (mostly from the State of Amazonas), including one returning to Italy from Brazil (Maggi et al., 2021). 117

118 Lastly, on 17 January 2021, public health officials announced that the SARS-CoV-2 GH, lineage 119 B.1.429 (GISAID) – also termed CAL.20C – has become increasingly common in multiple 120 Californian counties and has been responsible for several large COVID-19 outbreaks in that state. 121 All of these variants have characteristic mutations, the most significant of which are located in the 122 gene encoding the spike (S) protein (Li et al., 2020; Pillay et al., 2020). 123 The so-called 'UK variant' 20I/501Y.V1 is characterized by 23 mutations: 14 nonsynonymous 124 mutations, 3 deletions and 6 synonymous mutations affecting ORF1ab, S, ORF8, and N (Chand et 125 al, 2021). Mutations in the gene that encodes for the S protein, which is associated with viral entry 126 into cells, has attracted the most attention. Ten mutations are documented in the S protein of the UK 127 variant. Two of these, the N501Y (an asparagine to tyrosine amino acid substitution in the receptor 128 binding domain) and the HV69-70del (a 6-base deletion), had already been circulating globally 129 before merging into this new variant. The most relevant changes in the 20I/501Y.V1 variant are 130 likely to be the N501Y mutation and the Y144del - a deletion potentially contributing to spike 131 surface variation. The N501Y mutation is in the receptor binding domain (RDB), important to 132 ACE2 binding and antibody recognition. It is likely to enhance the transmissibility of the virus by 133 improving the S protein's affinity for the host's ACE2 receptor. In vitro (Starr et al., 2020) and 134 animal experiments (Gu et al., 2020) seem to confirm this hypothesis. 135 The 20H/501Y.V2 variant, first detected in South Africa, displays the same N501Y mutation (as well as the D614G) as the UK variant, but this mutation is thought to have arisen independently in 136 137 the two lineages (WHO 2020b). It also carries additional mutations (the most common are L18F, K417N, E484K and K417N) in the S protein, which are not usually present in the UK strain, though 138 139 mutation E484K has been recently detected in 21 B.1.1.7 sequences in UK (PHE, 2021). 140 Furthermore, 501Y.V2 does not have the HV69-70del characterizing the UK variant, but presents in 141 about 85% of sequences another deletion in the S region, that of amino acids 242 to 244 (LAL242-244del). 142

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

The new variant from Brazil, 20J/501Y.V3, harbors 12 mutations in the S protein, some of which it shares with either the 'UK variant' (N501Y and D614G) or the 'South African variant' (L18F, E484K, N501Y, D614G). The Spanish variant 20E.EU1 is characterized by substitution A222V in the A domain of the S protein, a domain which is not considered to contribute directly to receptor binding or membrane fusion for SARS-CoV-2 (Hodcroft et al., 2020). The rapid emergence of variants worldwide highlights the importance of genetic surveillance of the SARS-CoV-2 pandemic. The risk of introduction and community spread of variants of concern in the EU/EEA countries is considered very high (ECDC, 2021b). WHO advises all countries to increase the routine sequencing of SARS-CoV-2 viruses where possible, and to share sequence data internationally through open-source platforms (WHO 2021). ECDC also recommends urgent analysis and sequencing of virus isolates to identify cases of the new variants in a timely manner (ECDC, 2021a). Currently, whole genome sequencing (WGS) of human isolates has resulted in over 591,000 complete genomes available in GISAID as of 23 February, 2021. A full genome approach (WGS), however, is time-consuming and costly, and requires specialized computational infrastructure and technical skills. Furthermore, WGS cannot be effectively performed in conditions of low virus titres, reduced sequence integrity and simultaneous occurrence of more than one genome. We developed a long PCR nested RT-PCR assay (~1500 bp), followed by conventional Sanger sequencing, to quickly screen for the different circulating variants or detect the introduction of possible novel variants. The assay amplifies a key region of the S gene, the region containing the major mutations of the UK, South African and Brazilian variants, as well as crucial mutations of other variants of clinical interest, like the 20E.EU1 that emerged in Spain, the mink-associated variant, and the CAL.20C variant identified in California (see Table 1). Preliminary studies on sequences available in GISAID and Nextclade were performed before application on field samples.

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

The first, aimed at verifying whether specific mutation combinations are sufficiently informative to screen for specific SARS-CoV-2 variants, and the second, a comparative study of full-length sequences and their corresponding ~1500 bp fragments to ascertain whether the different variants would be correctly assigned to their respective clades on the sole basis of the genome region amplified by the long nested PCR assay. We subsequently enhanced our method to allow variant detection in highly challenging matrices such as wastewater, where the amplification of long RNA fragments is difficult, by designing two additional short nested RT-PCRs targeting portions of the region spanned by the long assay. SARS-CoV-2 is excreted by both symptomatic and asymptomatic individuals that are infected with the novel coronavirus, and ends up in wastewater systems (Foladori et al., 2020). By analysing wastewater, it is therefore possible to obtain information on viruses circulating in the population served by a given Wastewater Treatment Plant (WTP). Previous studies have detected SARS-CoV-2 RNA in wastewater samples worldwide, highlighting environmental surveillance as a valuable tool potentially allowing us to detect peaks in virus circulation and estimate the proportion of individuals infected with SARS-CoV-2 in a given catchment area (Hart et al., 2020), thus contributing to inform public health interventions. All the assays were successfully tested on a 20I/501Y.V1 strain detected in Italy at the end of December 2020 (see Supplementary material), and on a Wuhan strain (clade 19A). Finally, the three assays were tested on a panel of field samples of clinical (viral isolates from swabs) and environmental (sewage) origin. The methods proposed could be used to perform targeted sequencing of clinical and environmental samples for screening and early detection of SARS-CoV-2 variants.

### MATERIALS AND METHODS

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

Primer design and preliminary in silico studies Primers were designed to capture key mutations of different variants. Such mutations (Table 1), potentially affecting viral infectivity and antigenicity, are located in the gene encoding the spike (S) protein. Primers (Table 2 and Figure 1) were designed using the Primer 3 software (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi). Ultimately, three assays were designed with different aims: a) A long nested RT-PCR (first cycle - PCR ID 979; nested assay - PCR ID 980, 1583-1592 bps) designed to screen for the presence of mutations characteristic of the three VOCs (20I/501Y.V1, 20H/501Y.V2, and 20J/501Y.V3), as well as other variants of interest such as 20E.EU1,CAL 20C, and mink variant, as shown in Table 1. b) A short nested RT-PCR (319-327 bps) amplifying a portion of the region targeted by the long assay (first cycle - PCR ID 972; nested assay - PCR ID 973) designed to reveal the presence of the mutations HV69-70del and Y144del (UK variant), D80A (South African variant), and D138Y (Brazilian variant). c) Another short nested RT-PCR (323 bps) amplifying a different portion of the region targeted by the long assay (first cycle - PCR ID 974; hemi-nested assay - PCR ID 975) designed to reveal the presence of the key mutation N501Y shared by different variants of concern. This amplicon can also reveal the presence of amino acid substitution A570D (combined with N501Y) of the 20I/501Y.V1 variant, and E484K (combined with the N501Y) of either the 20H/501Y.V2 or the 20J/501Y.V3 variant. It can also detect L452R of the Californian variant and Y453F of the mink variant. Before application to field samples, a preliminary in silico study was performed to examine the discriminatory potential of the specific mutations covered by our long assay, for SARS-CoV-2

218 variant identification. This was done using GISAID (https://www.gisaid.org/) and Nextclade 219 (https://nextstrain.org/). The GISAID study was performed on 20I/501Y.V1 (14 January 2021) and 220 20H/501Y.V2 (17 January 2021) using complete genomes (see Supplementary Materials). on 221 Overall, considering the characteristic mutations of 20I/501Y.V1 present in the ~ 1500 bp fragment 222 of the S gene chosen for the long assay (HV69-70del, Y144del, N501Y and A570D), the results 223 showed that among the complete genomes belonging to lineage GR B.1.1.7 any combination of two mutations was present at a frequency ranging from 97.6% to 99.4%. Furthermore, cluster analysis 224 225 attributed all of the sequences displaying at least two of the aforementioned mutations to the GR 226 B.1.1.7 lineage. As for the 20H/501Y.V2 variant, characteristic mutations such as D80A, E484K, 227 N501Y, LAL242-244del were present at a frequency ranging from 88.6 to 91.4%. Any combination 228 of two of these mutations was present in clade GH lineage B.1.351 at a frequency exceeding 84.2%, 229 and sequences displaying at least two of the mutations belonged to lineage B.1.351 in >99% of 230 cases. One significant exception was the E484K/N501Y combination, which belonged to lineage 231 GH B.1.351 in 96.8% of cases, due to its presence in the 20J/501Y.V3 (Brazilian) variant as well. 232 Based on this preliminary analysis, it was concluded that, for these two variants, the detection of a 233 combination of at least two mutations in the selected ~ 1500 bp fragment provided a strong 234 indication of the presence of the variant in question. 235 To further explore the discriminatory potential of our newly-designed long nested PCR for the 236 different SARS-CoV-2 variants, we compared the ~1500 bp fragments to their corresponding full-237 length sequences in terms of how they would be classified by Nextclade web tool. We therefore 238 created two FASTA files: one containing 30 full-length genomes, comprising five GISAID strains 239 for each of the following clades/variants: 19A (Wuhan, China), 20I/501Y.V1 (UK), 20H/501Y.V2 240 (South Africa), 20J/501Y.V3 (Brazil), 20E.EU1 (Spain), CAL.20C (California) as described in the 241 Supplementary Materials; and the other, derived from the first, containing the corresponding ~1500 242 bp fragments amplified by our long nested PCR assay. Both files were then analyzed using the

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

Nextclade web tool (nextstrain.org) in order to determine whether our nested assay (PCR ID 980) would yield similar results to those given by a full sequence analysis. Nextclade web tool assigned all the variants correctly on the sole basis of the genome region amplified by the PCR ID 980. The only significant exception was the 20I/501Y.V1 variant, which was incorrectly assigned to clade 20B. This misclassification, however, was due to a limitation of the Nextclade web tool, which, for the purposes of phylogenetic placement and clade assignment, uses only mutations and no gaps (https://github.com/nextstrain/nextclade/issues/311#issuecomment-765904855), and was therefore unable to take into consideration the deletions HV69-70del and Y144del for a correct assignment of our partial sequences of the S gene. Similarly, the two trees built with Nextclade, one based on fulllength genomes and the other based on ~1500 bp fragments, both correctly assigned all of the variants to the branches corresponding to clades 19A, 20H/501Y.V2, 20J/501Y.V3 and 20E.EU1. Only the 'UK variant' was placed at the base of the 20I/501Y.V1 branch (Figure 2). Primer validation on field samples and assay specificity The RNA of the 20I/501Y.V1 variant was obtained from a nasopharyngeal swab of an Apulian patient who had returned from the United Kingdom. The sample had previously been isolated on Vero E6 cells, fully sequenced (Experimental Zooprophylactic Institute of Puglia and Basilicata), and the sequence submitted to GISAID under reference hCoV-19/Italy/APU-IZSPB-399PT/2020. RNA from the Wuhan strain (kindly provided by the Robert Koch-Institute under the RefBio project) was included as control. Before being tested with the three nested PCR assays, both RNAs were standardized at a concentration ranging between  $10^2$  and  $10^3$  genome copies (g.c.)/ $\mu$ L using a previously published real-time RT-qPCR (La Rosa et al., 2021). The European Virus Archive global (EVAg) Coronavirus RNA specificity panel (kindly provided by the Erasmus University Medical Center, Rotterdam, The Netherlands), which includes both

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

Alfa- and Beta-coronaviruses (HCoV-NL63, HCoV-229E, HCoV-OC43, MERS-CoV, SARS-CoV and SARS-CoV-2), was used to assess the specificity of our newly-designed primers. Field samples i) Clinical samples: Seven SARS-CoV-2 RNA samples had previously been extracted from viruses originating from nasopharyngeal swabs following isolation on Vero E6 cells, and had been characterized by WGS and deposited in GISAID as belonging to clades 20A, 20B, 20E.EU1 (two samples each), and 20I/501Y.V1 (one sample). Viral concentrations in these samples were calculated as previously described (La Rosa et al., 2021) and found to be in excess of 10<sup>6</sup> g.c./uL. The samples were subsequently diluted to an approximate concentration of 10<sup>4</sup> g.c./µL before testing by nested PCR. ii) Environmental samples: a total of 34 sewage samples were included in the study. Twenty samples, collected in Wastewater Treatment Plants (WTPs) in Rome, Italy, between September and December 2020 (see Supplementary Materials), had been previously analyzed and found positive for SARS-CoV-2 following the procedure described in La Rosa et al. (2021). Briefly, concentration of sewage samples (250 ml) was performed by the two-phase polyethylene glycol-dextran separation method (WHO 2003) and nucleic acids were extracted using the NucliSens extraction system (bioMerieux, Marcy-l'Etoile, France). The eluted RNA (100 µl) was aliquoted and stored at -80°C until molecular analysis. Viral concentrations in these samples ranged from 2.0 to 37.8 g.c./ $\mu$ L of RNA (corresponding to 1.6×10<sup>3</sup> to 3.0×10<sup>4</sup> g.c./L of raw sewage). Eight sewage samples (4 composite and 4 grab) were collected between 21 and 25 January 2021 in 4 WTPs in the small town of Guardiagrele in Abruzzo (central Italy), where a cluster linked to the UK variant had been reported, to investigate whether the S mutations associated with 20I/501Y.V1 were detectable in the local sewage.

Furthermore, six sewage samples were collected between 5 and 8 February 2021 in the city of
Perugia, Umbria (central Italy), where the UK variant had been on the rise and the Brazilian variant
had been identified as well
(https://www.regione.umbria.it/documents/18/25027633/Ordinanza+n.14+del+6+
febbraio+2021.pdf).

Nested RT-PCR conditions

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

Following standardization of the protocol, SuperScript IV One-Step RT-PCR System with Platinum SuperFi RT-PCR Master mix (Invitrogen, Carlsbad, CA, USA) was used for the RT-PCR. The amplification conditions for the RT-PCR were as follows: reverse transcription at 45 °C for 10 min, denaturation at 98 °C for 2 min, followed by 35 cycles of 98 °C for 10 sec, 58 °C for 10 sec, 72 °C for either 30 sec (PCR ID 972 and 974) or 1 min (PCR ID 979), and a final extension at 72 °C for 5 min. Each of the three PCR reactions was performed using 1  $\mu$ L of each primer (10  $\mu$ M; Table 1) and either 4 µL of RNA in a final volume of 25 µL (clinical samples) or 8 µL of RNA in a final volume of 50 µL (environmental samples). After the first round of PCR, nested PCR was performed using the Phusion Hot Start II DNA Polymerase with GC buffer (Thermo Fisher Scientific, Waltham, MA, USA), 2 μL of the first PCR product, 1 μL of each primer (10 μM) and the following conditions: initial denaturation at 98 °C for 30 sec, followed by 45 cycles of 98 °C for 10 sec, 62 °C for 30 sec, 72 °C for either 30 sec (PCR ID 973 and 975) or 1 min (PCR ID 980), and a final extension at 72 °C for 10 min. Standard precautions were taken to avoid laboratory contamination. PCR products were observed by gel electrophoresis (2% agarose gel, stained with GelRed, Biotium; Fremont, CA, USA). To confirm amplifications, all products were purified from the PCR reaction or from gel using either Montage PCRm96 Micro-well Filter Plate (Millipore, Burlington, MA, USA) or GRS PCR & Gel Band Purification Kit (GRISP, Porto, Portugal) and

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

were sequenced (see Supplementary Materials) on both strands (Bio-Fab Research, Rome, Italy and Eurofins Genomics, Ebersberg, Germany). Sequences were submitted to GenBank under the accession numbers [to be assigned; submission IDs 4852387, 4852507, and 4852527]. Bioinformatics analysis The public database GISAID (Shu and McCauley, 2017) was used for BLAST searches and for mutation analysis. The Nextclade web tool v.012.0 (Hadfield et al., 2018) was used to compare study sequences to SARS-CoV-2 reference sequences, assign them to clades, and determine their position within the SARS-CoV-2 phylogenetic tree. As of 21 January 2021, the database includes 11 major clades (19A, 19B, 20A, 20B, 20C, 20D, 20E(EU1), 20F, 20G, 20I/501Y.V1, 20H/501Y.V2, 20J/501Y-V3). Auspice v2.0, an open-source interactive tool, was used to visualize phylogenetic trees. All SARS-CoV-2 mutations found in field samples were compared with the GISAID reference strain hCoV-19/Wuhan/WIV04/2019 using the CoVsurver mutation analysis tool (https://www.gisaid.org/epiflu-applications/covsurver-mutations-app/), which provides geographic and temporal distributions of SARS-CoV-2 mutations. **RESULTS** Primer validation and assay specificity All three newly designed PCR assays successfully amplified the two strains (the UK variant and the Wuhan strain) used for primer assessment.

341 Amplicon sequencing of the long fragment of the UK variant revealed the presence of mutations 342 HV69-70del, Y144del, N501Y and A570D characteristic of 20I/501Y.V1 (Table 1). Sequencing of 343 the short amplicons obtained using the other two assays confirmed this result. In the Nextclade tree 344 constructed using the ~1500 bps sequence, this isolate fell at the base of the branch corresponding 345 to clade 20I/501Y.V1, as predicted by the preliminary study we conducted with the UK variant in 346 Nextrain prior to primer design (Figure 2). As for the Wuhan strain, although amplification was 347 achieved with all three assays, the long PCR yielded a low amount of product, probably due to 348 RNA fragmentation, allowing only partial sequencing of the fragment. Identity with GenBank 349 reference sequence NC\_045512 was confirmed for amplicons provided by the two short assays. 350 Specificity of the three designed assays was confirmed on the EVAg Coronavirus RNA panel. 351 Amplicons of the expected size were obtained only for SARS-CoV-2 (sequencing confirmed 100% 352 identity to reference sequence NC\_045512) while no amplification was present for HCoV-NL63, 353 HCoV-229E, HCoV-OC43, MERS-CoV, and SARS-CoV RNAs. 354 355 Clinical samples 356 All of the seven SARS-CoV-2 RNAs extracted from viruses cultured on Vero E6 cells and 357 previously characterized by WGS were successfully amplified by the three newly developed assays. 358 Sequencing results of amplicons generated by the long PCR are summarized in Table 3. The 359 geographic and temporal occurrence of the mutations detected in the field samples, obtained using 360 the GISAID CoV surver: Mutation Analysis tool, is summarized in Supplementary Materials. 361 Sequences obtained by the long PCR confirmed the presence of the two variants in swab samples 362 (20E.EU1 in swab IDs 29 and 30, and 20I/501Y.V1 in swab ID 31). The UK variant, however, 363 could only be assigned to its correct lineage using the GISAID BLAST tool, given the 364 aforementioned limitation of the Nextclade tool. Samples free of mutations or carrying mutations 365 not specific to any VOC in the analyzed region (swab IDs 25 to 28) could not be differentiated and

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

assigned. Indeed, they showed 100% nt identity with different clades/lineages in GISAID, and were all classified as 19A by Nextclade (Table 3). All clinical samples also tested positive using the two short nested PCR assays. Amplicon sequencing of the short PCR fragments confirmed the sequences obtained using the long nested PCR in all samples. Environmental samples A total of 34 wastewater samples were tested with the three nested PCR assays. PCR and sequencing results are summarized in Table 4. The long nested RT-PCR did not amplify any of the 20 SARS-CoV-2-positive urban sewage samples collected from WTPs in Rome (IDs 3702 to 3815). Amplification, however, was achieved with PCR IDs 973 and 975 (8 and 10 samples, respectively, with an overlap of 5 samples). None of these samples displayed mutations indicative of VOCs. With regard to the 14 sewage samples collected from locations experiencing outbreaks of SARS-CoV-2 variants, the long nested PCR successfully amplified two of the eight samples collected in Guardiagrele, Abruzzo (IDs 3863 and 3865) and one of the six samples collected in Perugia, Umbria (ID 3947). The first two samples showed mutations characteristic of the Spanish variant (A222V), while the sample ID 3947 carried the mutation characteristic of the Brazilian variant (D138Y, R190S, K417T, E484K, and N501Y). The short assays - PCR ID 973, and PCR ID 975 successfully amplified 7 and 6 of the 14 sewage samples, respectively (with an overlap of 6 samples, including the three samples testing positive also by the long assay). Sequencing of fragments obtained by PCR 973 showed no mutations in the PCR amplicons originating from Guardiagrele. On the contrary, this short assay did find the presence of mutation D138Y, characteristic of the Brazilian variant, in three of the six samples collected in Perugia: ID 3944, 3945, and 3947. Another sample from Perugia (ID 3949), showed the aa substitution E96G, while the remaining two amplifications did not display any mutation.

The second short assay, PCR 975, confirmed the results obtained by PCR 973 on the amplified samples from Guardiagrele (IDs 3862 and 3863), namely, the absence of mutations indicative of VOCs. In the four samples collected in Perugia and identified as carrying mutations, on the other hand, this short assay (PCR 975) showed the key mutation N501Y. This mutation was combined with E484K in three of them (IDs 3944, 3945, and 3947), a combination present in both the Brazilian and the South African variants (see Table 1). The results of PCR 973, where all three samples showed the aa substitution D138Y, and those of the long assay showing one of them (ID 3847) to carry all 5 aa substitutions typical of the Brazilian variant, pointed to the presence of this VOC. The fourth sample from Perugia (ID3949) carried mutation N501Y along with A570D, a key signature of the UK variant.

#### **DISCUSSION**

SARS-CoV-2 sequence diversity was initially thought to be low, but an increasing number of variant sequences have since been detected, indicating that new mutations are continually emerging. Major variants discovered thus far include the UK variant (clade GR, lineage B.1.1.7), the South African variant (GH, lineage B.1.351), the Brazilian variant (clade GR, lineage P1), the variant from California (GH, B.1.429), the Spanish variant, the mink variant, and others. All these SARS-CoV-2 variants carry characteristic mutations (deletions and/or missense mutations) in different parts of the genome, some in important regions in terms of potential clinical significance, such as the gene coding for the spike protein (the S gene). The spike protein appears to be critical for cellular entry, and allows the virus to attach to the host cell (Pillar et al., 2020), which is why this protein is also a target for vaccine development and antigen testing.

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

The analysis of SARS-CoV-2 virus genomes can complement and support strategies to reduce the burden of COVID-19 (WHO, 2021). Whole genome sequencing has proven to be a powerful tool capable of helping us understand outbreak transmission dynamics and spill-over events and to screen for mutations with a potential impact on transmissibility, pathogenicity or countermeasures (e.g. diagnostics, antiviral drugs and vaccines) (WHO, 2020d). For this reason, the WHO recommends that routine sequencing of SARS-CoV-2 viruses be increased where possible, and sequence data be shared through open-source platforms (WHO 2020c). The ECDC similarly encourages EU/EEA states to sequence at least 500 randomly selected samples each week, and to prioritize samples from large outbreaks, or samples collected from travellers and individuals with an infection detected 2 weeks after vaccination (ECDC, 2021b). Whole genome sequencing demands substantial investment in terms of time and financial resources, however, and the acquisition of sufficient, high quality RNA to maximize sequencing yield and the validity of sequence data. In addition, bioinformatic analysis necessitates high-performance computational power and trained staff. To address some of these problems, we developed a rapid, inexpensive and sensitive long nested PCR assay to detect key changes in the S protein of SARS-CoV-2, indicative of the presence of VOCs 20I/501Y.V1, 20H/501Y.V2 and 20J/501Y.V3, as well as of other variants of clinical interest. This assay can be used as a first screening tool to select samples of interest for WGS characterization. Resources for genome sequencing would thus be optimized by allocating them to clinically relevant specimens. The region amplified by this long assay was specially chosen to reveal key mutations distinctive of main variants, as shown in Table 1. The discriminatory potential of the long PCR assay was initially explored in silico using GISAID and Nextclade. Phylogenetic trees predicted the ~1500 bps sequence of the S protein to have the same discriminatory power as the entire genome in assigning sequences with the S mutations characteristic of the VOCs to their corresponding clusters. The ability of primer pairs to amplify

441 SARS-CoV-2 RNA and the discriminatory power of the amplified fragments were then tested on 442 field samples, consisting of SARS-CoV-2 viral isolates, already been fully sequenced. All of the 443 clinical samples were successfully amplified with the long PCR. The 20I/501Y.V1 and 20E.EU1 444 variants present in the panel were correctly identified by the long assay. Other variants of concern, 445 like the Brazilian or the South African variants, were not available to us as field samples. Indeed, 446 only one case of the South African variant had been detected in Italy, in a man who landed at 447 Milan's Malpensa Airport from Africa at the end of January (https://www.ansa.it/lombardia/notizie/2021/02/ 03/a-varese-primo-caso-variante-sudafricana-in-448 449 <u>italia\_41b99448-367c-4000-ac88-9b3ae130d839. html</u>). Having downloaded the sequence (GISAID 450 EPI\_ISL\_1012924), we verified that it harbors the Spike mutations D80A, D215G, L242del, 451 L244del, K417N, E484K, and N501Y - all of which would have been detectable by our long PCR 452 assay. Similarly, only three cases of the Brazilian variant had been identified and fully sequenced 453 (GISAID EPI\_ISL\_875566 to ID EPI\_ISL\_875568) thus far in Italy. All these isolates carry the 454 characteristic Spike mutations D138Y, R190S E484K, K417T, and N501Y included in our assay. 455 Once we had confirmed that the developed PCR assay could be successfully used to screen for 456 variants in clinical samples, we went on to investigate whether this assay could also be used for the 457 screening of SARS-CoV-2 variants in complex matrices, such as urban wastewaters. Since the 458 amplification of long fragments poses specific challenges in such matrices, we also designed two short nested RT-PCR assays targeting portions of the region spanned by the long assay, to be used 459 460 in case of long PCR failure. A number of studies have demonstrated the added value of regular 461 surveillance of wastewaters in combination with other indicators for the management of the 462 pandemic and a recent document by the European Commission highlights the importance of 463 wastewater surveillance to allow screening among large population groups (European Commission, 464 2021). This can help public health authorities identify where more detailed analysis is needed and 465 speed up the detection of variants as part of an increased genomic and epidemiological surveillance.

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

Two recent papers have demonstrated that environmental surveillance can be used to study SARS-CoV-2 diversity (Crits-Christophet al, 2021; Martin et al., 2020). Crits-Christoph and co-workers sequenced SARS-CoV-2 RNA directly from sewage collected in the San Francisco Bay Area to generate complete and near-complete SARS-CoV-2 genomes, and found that the major consensus genotypes detected in the sewage were identical to clinical genomes from the region. Moreover, additional variants not found in clinical samples, were identified in wastewaters, suggesting that wastewater sequencing can provide evidence for recent introductions of viral lineages before they are detected by local clinical sequencing (Crits-Christophet al, 2021). Metagenomic analysis of environmental matrices is a complex task, however, with high operational costs and specific requirements in terms of bioinformatic skills. Martin and co-workers demonstrated changes in virus variant predominance during the COVID-19 pandemic by tracking SARS-CoV-2 in sewage using a nested RT-PCR approach targeting five different regions of the viral genome (Martin et al., 2020). Here, we adopted a similar approach, but concentrated on a unique region of the SARS-CoV-2 genome - the spike protein gene, which harbors several key mutations associated with known VOCs and other variants of interest. The newly-designed assays were therefore used on 34 sewage samples, including 20 SARS-CoV-2positive samples collected from WTPs in Rome between September and December 2020, eight sewage sample collected from a small town in Abruzzo where an outbreak of the UK variant was reported in mid-January (https://www.ansa.it/abruzzo/notizie/2021/01/18/covid-a-guardiagrele-36casi-da-variante-inglese\_fbfc1c88-649b-4f32-9042-d1f0648b2bbb.html), and six sewage samples collected in Perugia, Umbria, where, at the beginning of February, both UK and Brazilian variants have been documented by public health authorities (https://www.regione.umbria.it/documents/ 18/25027633/Ordinanza+n.14+del+6+febbraio+2021.pdf). As expected, only three of the samples could be amplified and successfully sequenced with the long PCR assay, one from Umbria, the others from Abruzzo. Wastewater is indeed a complex matrix

494

497

501

504

505

506

507

508

511

514

515

where the amplification of long fragments is seldom achieved, due to the presence of inhibitors, 492 nucleic acids of different origin, and fragmented target genomes, often in low amounts. The 493 sequences obtained by the long assay from samples collected in January in Abruzzo showed mutations characteristic of the Spanish variant, which was indeed the most common variant in the 495 EU till December 2020 (ECDC, 2021a). The sequence obtained from Perugia displayed instead the 496 mutations indicative of 20J/501Y.V3. Interestingly, this sample was collected on 6 February 2021 from a WTP serving the outskirts of Perugia, including the local hospital, which had reportedly 498 been experiencing nosocomial clusters of this variant, as per press releases issued by public health (https://www.ansa.it/umbria/notizie/2021/02/05/rezza-in-umbria-variante-brasiliana-in-499 officials 500 cluster-ospedalieri\_d50f6dce-9b78-443c-a0d8-0d23e16058a8.html; https://tg24.sky.it/salute-ebenessere/2021/02/08/covid-umbria). 502 As expected, the two short nested RT-PCR assays were more sensitive than the long one, 503 successfully amplifying about half of the tested sewage samples. No mutations of interest were detected in the samples collected in Rome and in Guardiagrele, Abruzzo, using the short assays, as the mutation A222V, characteristic of the Spanish variant, is not included in the short fragments. Conversely, sequences obtained from the sewage samples collected in Perugia, Umbria, showed the presence of mutations characteristic of the UK variant (one sample) and of the Brazilian variant (three samples, one of which was confirmed by the long assay). Both of these variants had been circulating in the area according to statements by public health authorities, but no genome 509 510 sequences were available at the time of the study. Comparing results obtained by the two nested PCRs for the same sample, concordant results were 512 obtained for the Brazilian variant (presence of mutation D138Y in the fragment obtained by PCR 513 973, and mutations E484K/N501Y in the amplicon of PCR 975). In contrast, the sample harboring mutations of the UK variant in the region amplified by PCR 975 (N501Y and A570D) did not show the expected mutations (HV69-70del and Y144del) in the region amplified by PCR 973. This

524

526

527

528

531

533

534

535

537

538

539

516 exposes a limit of the combined use of two short PCR assays. Since different SARS-CoV-2 strains may coexist in a single sewage sample, the use of separate tests may result in each of the tests 518 amplifying a sequence belonging to a different strain. However, our GISAID in silico study showed 519 the combination of the N501Y and A570D mutations to strongly suggest that the sequence carrying 520 them belongs to lineage GR B.1.1.7. Furthermore, we only performed classical Sanger sequencing 521 on PCR amplicons, and this approach may underestimate the existence of some, possibly less 522 common, sequences. Our next goal is therefore to combine the protocol with NGS on PCR 523 amplicons for a more in-depth analysis of sequences, as successfully applied to enteric viruses (Suffredini et al., 2018; Iaconelli et al, 2017). 525 To our knowledge, this is the first evidence of the presence of sequences harboring key mutations of 20I/501Y.V1 and 20J/501Y.V3, as well as of the Spanish variant in urban wastewaters, highlighting the potential contribution of wastewater surveillance to explore SARS-CoV-2 diversity. Moreover, we demonstrated the potential of this approach, based on nested amplification followed by conventional Sanger sequencing, to allow the rapid identification of specific VOCs in the catchment 529 530 of any given WTP to quickly identify areas where the intensification of clinical surveillance and/or targeted preventive intervention is required. 532 In conclusion, the method we propose can be used to rapidly screen SARS-CoV-2-positive samples for VOCs and other variants of clinical interest. Compared with WGS, conventional RT-PCR followed by Sanger sequencing can be performed routinely at low cost and does not require specialized expertise to interpret the results. Through the targeting of key mutations, this approach could enable the rapid screening of samples and the identification of samples to submit to WGS. 536 Moreover, the long nested RT-PCR described here can provide significant, albeit partial, molecular information for samples in which low amounts or poor quality SARS-CoV-2 RNA hamper the successful application of WGS. The approach can also be applied to environmental samples for the 540 purposes of SARS-CoV-2 wastewater-based epidemiology, to explore the possible presence of VOCs or other variants of clinical interest, therefore highlighting geographical areas where an enhancement of clinical monitoring could be beneficial.

Due to an increase in the prevalence of new SARS-CoV2 variants with possible clinical implications, monitoring the spread of different variants in the general population in a timely, cost-effective manner is of utmost importance. The proposed method can contribute to achieve this goal.

Declaration of interests

549

We declare no competing interests.

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

Acknowledgments

This publication was supported by the European Virus Archive Global (EVA-GLOBAL) project, which provided the coronavirus RNA panel for the assessment of our in-house PCR. The EVA-GLOBAL project, in turn, received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 871029. Our thanks go to "Project RefBio - Germany's contribution to strengthen the bio-analytical reference laboratories in the UNSGM (2017-2021), EQAE on SARS-CoV-2 (2020), Centre for Biological Threats and Special Pathogens (ZBS 1-3) at RKI (Project Coordinator), Berlin, Germany" for providing the Wuhan strain. We also thank Stefano Fontana for his insightful comments. We thank Luigina Serrecchia, Viviana Manzulli, Valeria Rondinone, Ines della Rovere, Fiorenza Petruzzi and Mr. Guido Asturio for their technical support. We acknowledge the support of Utilitalia, Italian federation of energy, water and environmental services, and ACEA ATO2 for wastewater sampling in Rome. We also thank Tommaso Pagliani and Fabio Campitelli of SASI SpA (Società Abruzzese per il Servizio Idrico Integrato) and the Municipal Authorities for allowing wastewater collection in Guardiagrele (CH), Abruzzo, and Tiziana Buonfiglio, Andrea Vitali, Paolo Meniconi, Massimo Lorenzetti Renzetti and Marino Burini, Umbra Acque SpA, for allowing wastewater collection in Perugia, Umbria.

## References

571

- 572 Bartolini B, Rueca M, Ernesto C, Gruber M, Messina F, Giombini E, Ippolito G, Capobianchi
- 573 MR, Di Caro A. The newly introduced SARS-CoV-2 variant A222V is rapidly spreading in Lazio
- 574 region, Italy. medRxiv 2020.11.28.20237016; doi: https://doi.org/10.1101/2020.11.28.20237016
- 575 CDC, 2020. Interim: Implications of the Emerging SARS-CoV-2 Variant VOC 202012/01. Interim:
- 576 Implications of the Emerging SARS-CoV-2 Variant VOC 202012/01 | CDC, accessed on 12
- 577 January, 2021.
- 578 Chand, Meera; Hopkins, Susan; Dabrera, Gavin; Achison, Christina; Barclay, Wendy; Ferguson,
- Neil; Volz, Erik; Loman, Nick; Rambaut, Andrew; Barrett, Jeff (21 December 2020). <u>Investigation</u>
- 580 of novel SARS-COV-2 variant: Variant of Concern 202012/01 (PDF)(Report). Public Health
- 581 England. Retrieved 12 january 2021.
- 582 China CDC Weekly. The Epidemiological Characteristics of an Outbreak of 2019 Novel
- 583 Coronavirus Diseases (COVID-19) China, 2020, COVID-19.pdf.pdf (onb.it)
- 584 Cleemput S, Dumon W, Fonseca V, Karim WA, Giovanetti M, Alcantara LC, Deforche K, de
- 585 Oliveira T. Genome Detective Coronavirus Typing Tool for rapid identification and
- characterization of novel coronavirus genomes. bioRxiv [Preprint]. 2020 Feb 2:2020.01.31.928796.
- 587 doi: 10.1101/2020.01.31.928796. Update in: Bioinformatics. 2020 Jun 1;36(11):3552-3555. PMID:
- 588 32511309; PMCID: PMC7217295.
- 589 Conti P, Caraffa A, Gallenga CE, Kritas SK, Frydas I, Younes A, Di Emidio P, Tetè G, Pregliasco
- 590 F, Ronconi G. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a
- vaccine problem. J Biol Regul Homeost Agents. 2021 Feb 24;35(1). doi: 10.23812/21-3-E. Epub
- 592 ahead of print. PMID: 33377359.

- 593 Crits-Christoph A, Kantor RS, Olm MR, Whitney ON, Al-Shayeb B, Lou YC, Flamholz A,
- 594 Kennedy LC, Greenwald H, Hinkle A, Hetzel J, Spitzer S, Koble J, Tan A, Hyde F, Schroth G,
- 595 Kuersten S, Banfield JF, Nelson KL. Genome Sequencing of Sewage Detects Regionally Prevalent
- 596 SARS-CoV-2 Variants. mBio. 2021 Jan 19;12(1):e02703-20. doi: 10.1128/mBio.02703-20. PMID:
- 597 33468686.
- 598 ECDC, 2020. European Centre for Disease Prevention and Control, 2020. Threat Assessment Brief:
- 599 Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the
- 600 United Kingdom. Threat Assessment Brief: Rapid increase of a SARS-CoV-2 variant with multiple
- 601 spike protein mutations observed in the United Kingdom (europa.eu), accessed on 12 January,
- 602 2021.
- 603 ECDC, 2021a. European Centre for Disease Prevention and Control, 2020. Risk related to spread of
- new SARSCoV-2 variants of concern in the EU/EEA 29 December 2020
- 605 ECDC, 2021b. European Centre for Disease Prevention and Control, 2021. Risk of spread of new
- 606 SARS-CoV-2 variants of concern in the EU/EEA first update (europa.eu) ECDC
- 607 EUROPEAN COMMISSION, 2021. HERA Incubator: Anticipating together the threat of COVID-
- 608 19 variants <a href="https://ec.europa.eu/info/sites/info/files/communication-hera-incubator-anticipating-">https://ec.europa.eu/info/sites/info/files/communication-hera-incubator-anticipating-</a>
- 609 <u>threat-covid-19-variants\_en.pdf</u>
- 610 Foladori P, Cutrupi F, Segata N, Manara S, Pinto F, Malpei F, Bruni L, La Rosa G. SARS-CoV-2
- 611 from faeces to wastewater treatment: What do we know? A review. Sci Total Environ. 2020 Nov
- 612 15;743:140444. doi: 10.1016/j.scitotenv.2020.140444. Epub 2020 Jun 24. PMID: 32649988;
- PMCID: PMC7311891.GISAID 2020, UK reports new variant, termed VUI 202012/01. GISAID -
- 614 UK reports new variant, termed VUI 202012/01, accessed on 12 January, 2021.

- 615 Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage —
- 616 United States, December 29, 2020–January 12, 2021. MMWR Morb Mortal Wkly Rep. ePub: 15
- 617 January 2021. DOI: <a href="http://dx.doi.org/10.15585/mmwr.mm7003e2external.icon">http://dx.doi.org/10.15585/mmwr.mm7003e2external.icon</a>.
- 618 Groves DC, Rowland-Jones SL, Angyal A. The D614G mutations in the SARS-CoV-2 spike
- 619 protein: Implications for viral infectivity, disease severity and vaccine design [published online
- 620 ahead of print, 2020 Nov 5]. Biochem Biophys Res Commun. 2020;S0006-291X(20)32038-6.
- 621 doi:10.1016/j.bbrc.2020.10.109
- 622 Gu, H. et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science 369
- 623 (2020).
- 624 Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko P, Bedford T, Neher
- RA. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics. 2018 Dec 1;34(23):4121-
- 626 4123. doi: 10.1093/bioinformatics/bty407. PMID: 29790939; PMCID: PMC6247931.
- 627 Hammer AS, Quaade ML, Rasmussen TB, Fonager J, Rasmussen M, Mundbjerg K, Lohse L,
- 628 Strandbygaard B, Jørgensen CS, Alfaro-Núñez A, Rosenstierne MW, Boklund A, Halasa T,
- 629 Fomsgaard A, Belsham GJ, Bøtner A. SARS-CoV-2 Transmission between Mink (Neovison vison)
- 630 and Humans, Denmark. Emerg Infect Dis. 2020 Nov 18;27(2). doi: 10.3201/eid2702.203794. Epub
- 631 ahead of print. PMID: 33207152.
- 632 Hart OE, Halden RU. Computational analysis of SARS-CoV-2/COVID-19 surveillance by
- 633 wastewater-based epidemiology locally and globally: Feasibility, economy, opportunities and
- 634 challenges. Sci Total Environ. 2020 Aug 15;730:138875. doi: 10.1016/j.scitotenv.2020.138875.
- 635 Epub 2020 Apr 22. PMID: 32371231; PMCID: PMC7175865.

- 636 Hodcroft EB, Zuber M, Nadeau S, Crawford KHD, Bloom JD, Veesler D, Vaughan TG, Comas I,
- 637 Candelas FG, Stadler T, Neher RA. Emergence and spread of a SARS-CoV-2 variant through
- 638 Europe in the summer of 2020. medRxiv [Preprint]. 2020 Nov 27:2020.10.25.20219063. doi:
- 639 10.1101/2020.10.25.20219063. PMID: 33269368; PMCID: PMC7709189.
- 640 Iaconelli M, Valdazo-González B, Equestre M, Ciccaglione AR, Marcantonio C, Della Libera S, La
- 641 Rosa G. Molecular characterization of human adenoviruses in urban wastewaters using next
- 642 generation and Sanger sequencing. Water Res. 2017 Sep 15;121:240-247. doi:
- 643 10.1016/j.watres.2017.05.039. Epub 2017 May 19. PMID: 28550812.
- 644 . Guthrie JL, Teatero S, Zittermann S, Chen Y, Sullivan A, Rilkoff H, Joshi E, Sivaraman K, de
- 645 Borja R, Sundaravadanam Y, Laszloffy M, Heisler L, Allen VG., Simpson JT., Fittipaldi N.
- 646 Detection of the Novel SARS-CoV-2 European Lineage B.1.177 in Ontario, Canada.
- medRxiv 2020.11.30.20241265; doi: https://doi.org/10.1101/2020.11.30.20241265
- 648 Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N, Giorgi EE,
- 649 Bhattacharya T, Foley B, Hastie KM, Parker MD, Partridge DG, Evans CM, Freeman TM, de Silva
- 650 TI; Sheffield COVID-19 Genomics Group, McDanal C, Perez LG, Tang H, Moon-Walker A,
- Whelan SP, LaBranche CC, Saphire EO, Montefiori DC. Tracking Changes in SARS-CoV-2 Spike:
- 652 Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020 Aug 20;182(4):812-
- 653 827.e19. doi: 10.1016/j.cell.2020.06.043. Epub 2020 Jul 3. PMID: 32697968; PMCID:
- 654 PMC7332439.
- 655 La Rosa G, Mancini P, Bonanno Ferraro G, Veneri C, Iaconelli M, Bonadonna L, Lucentini L,
- 656 Suffredini E. SARS-CoV-2 has been circulating in northern Italy since December 2019: Evidence
- 657 from environmental monitoring. Sci Total Environ. 2021 Jan 1;750:141711. doi:
- 658 10.1016/j.scitotenv.2020.141711. Epub 2020 Aug 15. PMID: 32835962; PMCID: PMC7428442.

- 659 Leung K, Shum MH, Leung GM, Lam TT, Wu JT. Early transmissibility assessment of the N501Y
- 660 mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Euro Surveill.
- 661 2021 Jan;26(1):2002106. doi: 10.2807/1560-7917.ES.2020.26.1.2002106. PMID: 33413740;
- 662 PMCID: PMC7791602.
- Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, Zhao C, Zhang Q, Liu H, Nie L, Qin H, Wang M, Lu Q,
- 664 Li X, Sun Q, Liu J, Zhang L, Li X, Huang W, Wang Y. The Impact of Mutations in SARS-CoV-2
- 665 Spike on Viral Infectivity and Antigenicity. Cell. 2020 Sep 3;182(5):1284-1294.e9. doi:
- 666 10.1016/j.cell.2020.07.012. Epub 2020 Jul 17. PMID: 32730807; PMCID: PMC7366990.
- 667 Maggi F, Novazzi F, Genoni A, Baj A, Spezia PG, Focosi D, Zago C, Colombo A, Cassani G,
- 668 Pasciuta R, Tamborini A, Rossi A, Prestia M, Capuano R, Azzi L, Donadini A, Catanoso G, Grossi
- PA, Maffioli L, Bonelli G. Imported SARS-COV-2 Variant P.1 Detected in Traveler Returning
- 670 from Brazil to Italy. Emerg Infect Dis. 2021 Feb 10;27(4). doi: 10.3201/eid2704.210183. Epub
- 671 ahead of print. PMID: 33567246.
- 672 Mahase, 2020. Covid-19: What have we learnt about the new variant in the UK?
- 673 *BMJ* 2020; 371 doi: <a href="https://doi.org/10.1136/bmj.m4944">https://doi.org/10.1136/bmj.m4944</a> (Published 23 December 2020)
- 674 Martin J, Klapsa D, Wilton T, Zambon M, Bentley E, Bujaki E, Fritzsche M, Mate R, Majumdar M.
- 675 Tracking SARS-CoV-2 in Sewage: Evidence of Changes in Virus Variant Predominance during
- 676 COVID-19 Pandemic. Viruses. 2020 Oct 9;12(10):1144. doi: 10.3390/v12101144. PMID:
- 677 33050264; PMCID: PMC7601348.
- 678 Martin J, Klapsa D, Wilton T, Zambon M, Bentley E, Bujaki E, Fritzsche M, Mate R, Majumdar M.
- 679 Tracking SARS-CoV-2 in Sewage: Evidence of Changes in Virus Variant Predominance during
- 680 COVID-19 Pandemic. Viruses. 2020 Oct 9;12(10):1144. doi: 10.3390/v12101144. PMID:
- 681 33050264; PMCID: PMC7601348.

- 682 Martínez-Puchol S, Rusiñol M, Fernández-Cassi X, Timoneda N, Itarte M, Andrés C, Antón A,
- 683 Abril JF, Girones R, Bofill-Mas S. Characterisation of the sewage virome: comparison of NGS
- tools and occurrence of significant pathogens. Sci Total Environ. 2020 Apr 15;713:136604. doi:
- 685 10.1016/j.scitotenv.2020.136604. Epub 2020 Jan 8. PMID: 31955099.
- 686 NERVTAG, 2020. New and Emerging Respiratory Virus Threats Advisory Group. NERVTAG
- 687 meeting on SARS-CoV-2 variant under investigation VUI-202012/01, 18 December 2020.
- 688 NERVTAG meeting minutes on SARS-CoV-2 variant under investigation. 18 December
- 689 (khub.net), accessed on 12 January, 2021.
- 690 NIID, 2021. Brief report: New Variant Strain of SARS-CoV-2 Identified in Travelers from Brazil.
- 691 PUBLISHED: 12 JANUARY 2021. Brief report: New Variant Strain of SARS-CoV-2 Identified in
- Travelers from Brazil (niid.go.jp). Accessed on 16 January 2021.
- 694 Public Health England (PHE) 2021. Investigation of novel SARS-CoV-2 variant: Variant of
- 695 Concern 202012/01, Technical briefing 5. 2020 [updated January 2021]. Available from:
- 696 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\_data/file/9
- 697 57504/Variant of Concern VOC 202012 01 Technical Briefing 5 England.pdf
- 698 Pillay TS. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. J Clin
- 699 Pathol. 2020 Jul;73(7):366-369. doi: 10.1136/jclinpath-2020-206658. Epub 2020 May 6. PMID:
- 700 32376714.

- 701 Ester C Sabino, Lewis F Buss, Maria P S Carvalho, Carlos A Prete Jr, Myuki A E Crispim, Nelson
- 702 A Fraiji, Rafael H M Pereira, Kris V Parag, Pedro da Silva Peixoto, Moritz U G Kraemer, Marcio K
- 703 Oikawa, Tassila Salomon, Zulma M Cucunuba, Márcia C Castro, Andreza Aruska de Souza Santos,

- 704 Vítor H Nascimento, Henrique S Pereira, Neil M Ferguson, Oliver G Pybus, Adam Kucharski,
- 705 Michael P Busch, Christopher Dye, Nuno R Faria. Resurgence of COVID-19 in Manaus, Brazil,
- 706 despite high seroprevalence. The Lancet, Published:January 27,
- 707 2021DOI:https://doi.org/10.1016/S0140-6736(21)00183-5
- 708 Starr, Tyler N., Allison J. Greaney, Sarah K. Hilton, Daniel Ellis, Katharine H. D. Crawford, Adam
- 709 S. Dingens, Mary Jane Navarro, et al. 2020. "Deep Mutational Scanning of SARS-CoV-2 Receptor
- 710 Binding Domain Reveals Constraints on Folding and ACE2 Binding." Cell 182 (5): 1295–
- 711 1310.e20.
- 712 Statens Serum Institut, Copenhagen S, DENMARK, 2020. Preliminary rapport on SARS-CoV-2
- 713 spike mutations arising in Danish mink, 2 their spread to humans and neutralization data. SARS-
- 714 CoV-2 spike mutations arising in Danish mink and their spread to 5 humans
- 715 Suffredini E, Iaconelli M, Equestre M, Valdazo-González B, Ciccaglione AR, Marcantonio C, Della
- 716 Libera S, Bignami F, La Rosa G. Genetic Diversity Among Genogroup II Noroviruses and
- 717 Progressive Emergence of GII.17 in Wastewaters in Italy (2011-2016) Revealed by Next-
- 718 Generation and Sanger Sequencing. Food Environ Virol. 2018 Jun;10(2):141-150. doi:
- 719 10.1007/s12560-017-9328-y. Epub 2017 Nov 28. Erratum in: Food Environ Virol. 2018 May 4;:
- 720 PMID: 29185203.
- 721 Volz E, Hill V, McCrone JT, Price A, Jorgensen D, O'Toole A, Southgate J, Johnson R, Jackson B,
- 722 Nascimento FF, Rey SM, Nicholls SM, Colquhoun RM, da Silva Filipe A, Shepherd J, Pascall DJ,
- 723 Shah R, Jesudason N, Li K, Jarrett R, Pacchiarini N, Bull M, Geidelberg L, Siveroni I; COG-UK
- 724 Consortium, Goodfellow I, Loman NJ, Pybus OG, Robertson DL, Thomson EC, Rambaut A,
- 725 Connor TR. Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and

- 726 Pathogenicity. Cell. 2021 Jan 7;184(1):64-75.e11. doi: 10.1016/j.cell.2020.11.020. Epub 2020 Nov
- 727 19. PMID: 33275900; PMCID: PMC7674007.
- 728 Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data from vision to reality.
- 729 Euro Surveill. 2017 Mar 30;22(13):30494. doi: 10.2807/1560-7917.ES.2017.22.13.30494. PMID:
- 730 28382917; PMCID: PMC5388101.
- 731 Suffredini E, Iaconelli M, Equestre M, Valdazo-González B, Ciccaglione AR, Marcantonio C, Della
- 732 Libera S, Bignami F, La Rosa G. Genetic Diversity Among Genogroup II Noroviruses and
- 733 Progressive Emergence of GII.17 in Wastewaters in Italy (2011-2016) Revealed by Next-
- 734 Generation and Sanger Sequencing. Food Environ Virol. 2018 Jun;10(2):141-150. doi:
- 735 10.1007/s12560-017-9328-y. Epub 2017 Nov 28. Erratum in: Food Environ Virol. 2018 May 4;:
- 736 PMID: 29185203.
- 737 WHO, 2020a. WHO Director-General's opening remarks at the media briefing on COVID-19 11
- 738 March 2020. 11 March 2020
- 739 WHO, 2020b. Emergencies preparedness, response. SARS-CoV-2 mink-associated variant strain –
- 740 <u>Denmark Disease Outbreak News.6 November 2020. WHO | SARS-CoV-2 mink-associated variant</u>
- 741 <u>strain Denmark</u>
- 742 WHO 2020c. Emergencies preparedness, response. SARS-CoV-2 Variant, WHO | SARS-CoV-2
- 743 Variants
- 744 WHO 2020d. SARS-CoV-2 Variant United Kingdom of Great Britain and Northern Ireland
- Disease Outbreak News, 21 December 2020 WHO | SARS-CoV-2 Variant United Kingdom of
- 746 Great Britain and Northern Ireland

- 747 WHO, 2021. Genomic sequencing of SARS-CoV-2 A guide to implementation for maximum
- 748 impact on public health 8 January 2021. <u>9789240018440-eng.pdf</u>

750

33

Figure 1. Positions of the primers in the newly designed PCR assays in the Spike gene of SARS-CoV-2




Figure 2. Nextclade web tool phylogenetic trees for representative strains of the different variants using the full genome or the Spike partial gene fragment amplified with PCR ID 980 - nextstrain.org with ad hoc modifications.




Table 1. Mutations indicative of the main SARS-CoV-2 VOC detectable by the newly designed PCR assays

Variant	Nucleotide position in the S gene																			
variani	207	210	240	414	432	456	570	645	666	726	729	732	735	738	1251	1356	1359	1452	1503	1710
20I/501Y.V1 (GR, B.1.1.7) 20H/501Y.V2	H69 del	V70 del	D80A		Y144 del			D215G		L242H	A243	L244	H245	P246I	K417N			F/8/K	N501Y N501Y	A570D
(GH, B.1.351) 20J/501Y.V3 (GR, P1)			DOOA	D138Y			R190S			L2 <del>4</del> 211	del	del	del	K2401	K417T				N501Y	
20E.EU1 (GV, B.1.177) CAL 20C						W152C			A222V							L452R				
(GH, B.1.429) Mink cluster V (GR, B.1.1.298)	H69 del	V70 del															Y453F			
PCR ID		PCR	973 (17	(1-452)																
(nt position in the S gene)	PCR 975 (1436-1'								6-1719)											
	PCR 980 (171-1719)																			

Table 2: Primers and PCRs used in this study

PCR ID	Prime	r ID and sequence (5'-3')	Positions *	Amplicon (bps)		
972	2319	ACCCTGACAAAGTTTTCAGATCCT	21675-21698	1 <sup>st</sup> cycle		
	2320	GCTGAGAGACATATTCAAAAGTGCA	22082-22058	399 to 408 bps		
973	2321	TTCAACTCAGGACTTGTTCTTACC	21709-21732	nested		
	2322	TCTGAACTCACTTTCCATCCAA	22036-22015	319 to 327 bps		
974	2323	TTGTTTAGGAAGTCTAATCTCAAACC	22925-22950	1 <sup>st</sup> cycle		
	2326	GTGGATCACGGACAGCATC	23300-23282	375 bps		
975	2325	CTATCAGGCCGGTAGCACAC	22978-22997	hemi-nested		
	2326	GTGGATCACGGACAGCATC	23300-23282	323 bps		
979	2319	ACCCTGACAAAGTTTTCAGATCCT	21675-21698	1 <sup>st</sup> cycle		
919	2324	CCTGATAAAGAACAGCAACCTG	23402-23381	1719**-1728 bps		
980	2321	TTCAACTCAGGACTTGTTCTTACC	21709-21732	nested		
	2326	GTGGATCACGGACAGCATC	23300-23282	1583**-1592 bps		

<sup>\*</sup> Reference genome NC45512.2 (Wuhan)

<sup>\*\*</sup> Expected size for the 'UK variant'

Table 3: Variant analysis of clinical samples obtained using PCR ID 980 and different bioinformatics tools

Sample ID Identification based on WGS		Mutation map <sup>1</sup>	GISAID blast	Nextclade	
swab_25	G B.1 / 20A	- -	Not assignable <sup>2</sup>	19A	
swab_26	G B.1 / 20A	D215H	Not assignable <sup>3</sup>	19A	
swab_27	GR B.1.1.316 / 20B	-	Not assignable <sup>2</sup>	19A	
swab_28	GR B.1.1.229 / 20B	-	Not assignable <sup>2</sup>	19A	
swab_29	GV B.1.177 / 20E EU1	A222V	GV_B.1.177	20E (EU1)	
swab_30	GV B.1.177 / 20E EU1	A222V	GV_B.1.177	20E (EU1)	
swab_31	GR B.1.1.7 / 20I/501Y.V1	H69del, V70del, Y144del, N501Y, A570D	GR/501Y.V1 (B.1.1.7)	20B	

<sup>&</sup>lt;sup>1</sup> Analysis with GISAID CoVsurver: Mutation Analysis (<a href="https://www.gisaid.org/epiflu-applications/covsurver-mutations-app/">https://www.gisaid.org/epiflu-applications/covsurver-mutations-app/</a>)

<sup>&</sup>lt;sup>2</sup> 100% identity with sequences assigned to the following clades: GR\_B.1.1.222; GR\_B.1.1.70; GR\_B.1.1.119; GR\_B.1.1.28; GR\_B.1.1.316; GR\_B.1.1.33; GR\_B.1.1.103; GH\_B.1.2; GH\_B.1.425; G\_B.1; G\_B.1.91; GH\_B.1.4703 

<sup>3</sup> 100% identity with sequences assigned to the following clades: G\_B.1; GH\_B.1.2; GR\_B.1.1.47; GR\_B.1.1.304; GR\_B.1.1.127; GR\_B.1.1.284; GR\_B.1.1.119; O\_B-13 

n.d. not done due to absence of PCR amplification

Table 4. Variant analysis of environmental samples obtained using PCR IDs 980, 973, and 975

Sample	Sampling	P	CR ID 980	PC	CR ID 973	PCR ID 975		
ID	location	result	mutations	result	mutations	result	mutations	
Archive sar	nples							
3716	Rome East	-		-		+	none	
3732	Rome North	-		+	none	+	none	
3737	Rome East	-		-		+	none	
3738	Rome East	-		+	none	+	none	
3740	Rome East	-		-		+	none	
3742	Rome Ostia	-		+	none	+	none	
3750	Rome North	-		-		+	none	
3798	Rome East	-		+	none	+	none	
3801	Rome East	-		+	none	-		
3802	Rome East	-		-		+	none	
3805	Rome East	-		+	none	-		
3808	Rome South	-		+	none	-		
3809	Rome Ostia	-		+	none	+	none	
Ad-hoc san	nples from outbre	ak locati	ions					
3862	Guardiagrele	-		+	none	+	none	
3863	Guardiagrele	+	A222V	+	none	+	none	
3865	Guardiagrele	+	A222V	+	none	-		
3944	Perugia	-		+	D138Y	+	E484K, N501Y	
3945	Perugia	-		+	D138Y	+	E484K, N501Y	
3947	Perugia	+	D138Y, R190S, K417T, E484K, and N501Y		D138Y	+	E484K, N501Y	
3949	Perugia	-		+	E96G	+	N501Y, A570D	

Samples IDs 3702, 3714, 3720, 3739, 3744, 3797, 3815, 3864, 3868, 3869, 3946 and 3948 did not provide amplification in any of the assays and were not included in the table.